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Manuscript
Abstract (221 words) 
Over the past 10 years, the available evidence on the treatment of malaria during pregnancy has 
increased substantially. Considering their relative ease of use, good sensitivity and specificity, 
histidine rich protein2 based rapid diagnostic tests are particularly appropriate for symptomatic 
pregnant women while they seem less appropriate for systematic screening as they will miss an 
important proportion of infections among asymptomatic women. The effect of pregnancy on the 
pharmacokinetics of antimalarial drugs varies greatly between studies and class of antimalarial 
drugs, emphasising the need for prospective studies in pregnant and non-pregnant women. For the 
treatment of malaria during the first trimester, international guidelines are currently being reviewed 
by the World Health Organization. For the second and third trimester of pregnancy, results from 
several trials have confirmed that artemisinin-based combination treatments are safe and 
efficacious, though tolerability and efficacy may vary by treatment. It is now essential to translate 
such evidence into policies and practice that benefit pregnant women in malaria-endemic countries. 
Access to parasitological diagnosis and/or appropriate antimalarial treatment in many countries and 
regions remains low. Therefore, there is a pressing need for research to identify quality 
improvement interventions targeting pregnant women and health providers. In addition, efficient 
and practical systems for pharmacovigilance are needed to further expand knowledge on the safety 
of antimalarials, particularly in the first trimester of pregnancy.  
  
Introduction 
All malaria infections in pregnancy should be treated promptly with safe and efficacious antimalarial 
drugs to prevent their harmful effects on the mother and foetus (1,2).  
Concerns about the potential for harm of new antimalarial treatments on pregnant women or their 
unborn baby has led to their systematic exclusion from clinical trials, resulting in limited information 
on their pharmacokinetics, safety, and efficacy during pregnancy (3–5), particularly for the first 
trimester (6,7). However, over the past 10 years (8), there has been substantial research on malaria 
in pregnancy, by the Malaria in Pregnancy Consortium (www.mip-consortium.org) and others, 
addressing knowledge gaps, and herein  we present a summary of the results. 
Search strategy 
Four separate systematic reviews were conducted, one for each of the major topic areas: diagnosis, 
efficacy, pharmacokinetics, safety, and access to treatment. Their respective search strategies are 
outlined in the supplemental appendix and results are provided below. 
Diagnosis 
Case management of malaria consists of identifying a suspect case, based on the presence of signs/ 
symptoms, and performing diagnostic testing followed by treatment if needed. The accuracy of 
diagnostic tests depends on parasite density. Microscopy with an experienced and well equipped 
microscopist has a detection threshold of 15 parasites per μL of blood (1) while for rapid diagnostic 
tests (RDT), which detect circulating parasite antigens, this may be as low as 200 parasites per μL(9). 
Such diagnostic tests (microscopy and RDTs) may be adequate for pregnant women with malaria 
symptoms as they usually have parasite densities above their detection thresholds (10). 
Nevertheless, the large majority of infections during pregnancy are asymptomatic, with low parasite 
densities, often not detected by microscopy. The public health importance of such infections is 
controversial as they have been associated with anaemia, lower mean Hb, low birth weight, and 
premature births in some studies (11) but not in others (12). Intermittent screening and treatment, a 
potential alternative to intermittent preventive treatment with sulfadoxine-pyrimethamine (SP) in 
places of high SP resistance or low malaria transmission, is based on the assumption that currently 
available tests, more specifically RDTs, should be able to identify most infections. This is probably 
not the case though, thanks to their ability to detect circulating parasite antigens, RDTs may be 
useful in diagnosing placenta malaria, particularly for P. falciparum (13). In a systematic review of 49 
studies, with microscopy of placental blood as the gold standard, RDTs sensitivity was 81% [95% CI 
55-93] and specificity 94% [95% CI 76-99], while polymerase chain reaction (PCR) had higher 
sensitivity (94%, 95% CI 86-98) but lower specificity (77%, 95% CI 71-82) (14). However, in Papua 
New Guinea, more than half of active placenta infections were not diagnosed by RDT, microscopy, or 
PCR on peripheral blood (15). Similar results were reported from Mozambique (16), possibly because 
of occult placental sequestration (15). Nevertheless, in Malawi, latent class analysis, which does not 
assume a gold standard, showed that RDT sensitivity and specificity on peripheral blood for 
diagnosing placenta malaria was 92.7% and 91.8%, respectively (17). As for peripheral infections, 
RDTs had similar (18,19) or lower (10) sensitivity than microscopy, with  histidine rich protein2 
(HRP2)-based RDT performing better that plasmodium lactate dehydrogenase (pLDH)-based RDTs 
(10,20). 
Considering their relative ease of use, good sensitivity and specificity, HRP2-based RDTs are 
particularly appropriate for symptomatic pregnant women while they are less appropriate for 
systematic screening as they will miss an important proportion of infections among asymptomatic 
pregnant women. The newly available ultra-sensitive RDT (Alere™ Malaria Ag P.f) should be 
evaluated for detecting  low-density infections in pregnant women.  
 
Treatment of uncomplicated malaria 
First trimester  
For P. falciparum malaria during the first trimester, the WHO recommends quinine with clindamycin 
for seven days (or quinine alone if clindamycin is not available) and, in case of failure or 
unavailability, an artemisinin-based combination therapy (ACT) or oral artesunate with clindamycin 
for seven days (2). This is based on data from 700 pregnant women exposed to artemisinin 
derivatives during the first trimester, and excludes a ≥4.2-fold increase in risk of major congenital 
defects (2). However, the Malaria Policy Advisory Committee recommended recently revising these 
guidelines on the basis of a recent meta-analysis (21,22).  
 
Non-falciparum malaria should be treated with chloroquine; in case of chloroquine-resistant 
infections, quinine is recommended (2).  
 
Second and third trimester 
Guidelines for the treatment of P. falciparum malaria in the second and third trimester are the same 
as for non-pregnant adults, i.e. any ACT recommended as national first-line treatment, namely 
artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine, dihydroartemisinin-
piperaquine, or artesunate plus sulfadoxine-pyrimethamine (2). A systematic review including 16 
randomized control trials done between 1998 and 2009 (23) presented ten trials testing  ACTs (three 
artesunate plus sulfadoxine-pyrimethamine, two artemether-lumefantrine, three artesunate-
mefloquine, one dihydroartemisinin-piperaquine and one artesunate with atovaquone-proguanil) 
versus either combinations without artemisinins or monotherapies. In most trials, ACTs had a PCR-
adjusted efficacy >90%, with the exception of artemether-lumefantrine at the Thai-Burmese border 
with an efficacy of 87% at day 42 (23), attributed to low drug concentrations and low antimalarial 
immunity (24). A systematic review and meta-analysis comparing the efficacy, safety, and tolerance 
of ACTs with that of quinine and other non-ACT antimalarials (azithromycin plus SP; SP plus 
amodiaquine) included 6 trials done between 1995 and 2009, three from sub-Saharan Africa 
(Malawi, Tanzania, Uganda) and three from Asia (Thailand), all of them included in the previous 
review (23), except the one in Uganda (25). ACTs were significantly more efficacious than oral 
quinine, had similar efficacy to non-ACTs in Africa and significantly higher efficacy in Thailand. Birth 
outcomes were similar between treatment arms, with the exception of mean birth weight that was 
significantly higher in ACT versus non-ACT recipients, indicating ACTs may clear parasites, including 
those in the placenta, more efficiently than other treatments (26). Furthermore, artemether-
lumefantrine was associated with decreased rates of moderate to high-grade haemozoin deposition 
in the placenta (13.3% versus 25.8%) compared to oral quinine in Uganda, indicating a protective 
effect against placental malaria (27).  
 
A large multicentre randomized open-label trial testing four ACTs (artemether-lumefantrine, 
artesunate-amodiaquine, artesunate-mefloquine, and dihydroartemisinin-piperaquine) in pregnant 
women with P. falciparum malaria was carried out between 2010 and 2013 in four sub-Saharan 
African countries (Burkina Faso, Ghana, Malawi, and Zambia). A total of 3,428 pregnant women were 
recruited and followed up until day 63 post-treatment and then at delivery. The PCR-adjusted cure 
rates for all ACTs ranged from 94.8% to 99.2%, within the pre-specified equivalence margin. 
Nevertheless, the cure rates in the artemether-lumefantrine  group were significantly lower than for 
the other treatments, which had similar high efficacy (28). The significantly lower unadjusted cure 
rates in the artemether-lumefantrine group (52.5%) than in the other treatment groups (artesunate-
amodiaquine: 82.3%; artesunate-mefloquine: 73.8%; dihydroartemisinin-piperaquine: 86.9%) 
indicate that in areas of intense transmission dihydroartemisinin-piperaquine may be preferable to 
artemether-lumefantrine because of its longer post-treatment prophylactic period.  
 
Recently, a few smaller trials carried out in sub-Saharan Africa (Nigeria (29) and Uganda(30)) 
confirmed the high efficacy of ACTs.    
  
In southern Papua New Guinea, Indonesia, dihydroartemisinin-piperaquine became the first line 
treatment for second and third trimester pregnant women in 2006, and this resulted in a decline of 
congenital malaria cases, from 3.2%  to 0.2%, with no case detected since 2008 (31). The 
implementation of dihydroartemisinin-piperaquine also resulted in a lower risk of malaria at 
delivery, early neonatal deaths (32), maternal severe anaemia, and low birth weight (33).   
 
Though chloroquine can be used for treating non-falciparum malaria (1), P. vivax resistance emerged 
in the 1980s in New Guinea and has spread to the Indonesian archipelago and Mekong region (34). 
Almost all antimalarial drugs with activity against P. falciparum demonstrate intrinsic activity against 
P. vivax asexual stages, with the exception of antifolate drugs (34). Therefore, vivax malaria can be 
treated with any ACT effective against P. falciparum, with the exception of artesunate plus 
sulfadoxine-pyrimethamine (2). ACTs rapidly clear P. vivax asexual stages though there is high 
variability in the occurrence of recurrent infection between 28 and 63 days post-treatment (34).  
Unfortunately, primaquine, the only available drug effective against the parasite’s liver stages, is 
contraindicated in pregnancy and breast feeding, due to the risk of haemolysis if the offspring is 
glucose-6-phospate dehydrogenase deficient (34); it can be administered when the woman has 
stopped breastfeeding.     
 
Treatment of complicated malaria 
Pregnant women have a higher risk of developing severe malaria. This is particularly true in low 
transmission settings, where it is often complicated by pulmonary oedema and hypoglycaemia (2). 
Intensive care and prompt parenteral antimalarial treatment are critical to the mother’s survival (1). 
A recent review on the treatment of severe malaria in all trimesters of pregnancy identified ten 
studies that reported clinical outcomes (35). The review supports WHO recommendation for 
intravenous artesunate as the drug of choice, or if unavailable, intramuscular artemether (2), though 
for the latter the absorption is less predictable, especially in patients with cardiovascular collapse 
(1). Parenteral quinine, though associated with recurrent hypoglycaemia, can be used when 
artesunate or artemether are not available (2). 
 
Until controlled clinical trials are conducted, severe non-falciparum malaria should be managed as 
severe falciparum malaria in intensive care settings with intravenous artesunate or quinine (34). 
 
Pharmacokinetics (Table 1) 
Pregnancy is associated with a number of physiological changes that can alter drug absorption, 
disposition, metabolism and excretion (36). It is therefore imperative to recognize pregnancy-related 
changes in pharmacokinetic properties since these may result in over- or under-exposure to 
antimalarials. Over-exposure might lead to maternal and foetal toxicity and under-exposure to 
therapeutic failures, resulting in poor pregnancy outcomes, maternal death, and increased risk of 
drug resistance (36,37). The current literature on the pharmacokinetic of antimalarials in pregnancy 
is often contradictory and based on small studies without non-pregnant control patients. Controlled 
prospective pharmacokinetic studies are needed to evaluate the pregnancy effect. Ideally, non-
pregnant controls should be matched by sex, malaria infection status, and age to control for 
confounding covariates, and evaluated with pharmacokinetic modelling approaches to quantify 
potential pregnancy-specific effects.  
Artemisinins 
Systemic drug exposure to artesunate and its active metabolite dihydroartemisinin, following oral 
administration of artesunate, was substantially lower in pregnant women with falciparum malaria on 
the Thai-Myanmar boarder than in historical (38) and post-partum controls (39,40). In one of these 
studies, malaria and pregnancy were shown to have opposite effects on the absorption of orally 
administered artesunate; malaria increased the oral bioavailability of artesunate by 87%, whereas 
pregnancy decreased the oral bioavailability by 23% (39). However, there was no evidence of 
pregnancy-related alteration on the pharmacokinetic properties of artesunate or dihydroartemisinin 
after intravenous administration, suggesting that standard treatment recommendations for severe 
malaria apply to pregnant women. A study carried out in Kinshasa, Democratic Republic Congo, 
comparing women during pregnancy and post-partum with non-pregnant controls confirmed an 
altered drug exposure in pregnant women (42% decreased exposure to dihydroartemisinin) after 
oral administration of artesunate (41,42). However, no difference was seen in the exposure to 
dihydroartemisinin in pregnant and non-pregnant women in Burkina Faso after oral artesunate 
treatment (43). 
The pharmacokinetic properties of artemether and its active metabolite dihydroartemisinin, after 
oral administration of artemether, are reported to be unaltered in two clinical studies in pregnant 
women and matched non-pregnant controls in Uganda and Tanzania (30,44). However, studies 
recruiting only pregnant women have reported lower drug exposures in pregnant women compared 
to historical controls (45–48).  
Contradictory results have also been presented regarding the systemic drug exposure to 
dihydroartemisinin, following oral administration in pregnant women and matched non-pregnant 
controls (49–52). In Thailand and Uganda, drug exposure was substantially lower (38% and 47%, 
respectively) in pregnant women (50) while in Papua New Guinea pharmacokinetic properties in 
pregnant women were unaltered (49).  
Thus, ACTs may need a dose adjustment (higher dose) but more information is needed. A recently-
published systematic review reached similar conclusions (53).  
 
4-amino-quinolines 
Drug exposure to chloroquine and its main metabolite desethylchloroquine was significantly reduced 
(25% and 45%, respectively) in pregnant women compared to age-matched non-pregnant women in 
Papua New Guinea when receiving three daily doses (450 mg/day) of chloroquine as intermittent 
preventive treatment (54). This was due to increased elimination of both chloroquine and 
desethylchloroquine during pregnancy. However, pharmacokinetic parameters of chloroquine or 
desethylchloroquine were not different between pregnant and non-pregnant Karen women with 
vivax malaria (55).  
No differences in the pharmacokinetic properties of amodiaquine or desethylamodiaquine  were 
found between pregnant women in the second and third trimesters with vivax malaria and the same 
women 3 months post-partum (56). Population pharmacokinetic modelling confirmed that 
pregnancy did not have a clinically relevant impact on the pharmacokinetics of amodiaquine or 
desethylamodiaquine, with no need of  dose adjustment (57).  
 
Contradictory results have been presented regarding the pharmacokinetic properties of piperaquine 
in pregnancy. There was no significant difference in total drug exposure to piperaquine between 
pregnant and non-pregnant women with falciparum malaria in Thailand (51). Population 
pharmacokinetic modelling showed similar effects of piperaquine on the relative bioavailability and 
elimination, resulting in a net effect of unaltered drug exposure, but a shorter elimination half-life in 
pregnant women (50). Similar results were obtained in pregnant and age- and weight-matched non-
pregnant Sudanese women with falciparum malaria (58,59). However, an approximately 40% lower 
exposure to piperaquine in pregnant than non-pregnant women has been reported in Papua New 
Guinea and Uganda (49,52).  
 
Quinoline methanols and related drugs 
No relevant differences were found in the exposure to mefloquine between pregnant women in 
their second and third trimester and matched non-pregnant women with falciparum malaria in 
Burkina Faso when treated with artesunate-mefloquine (43). However, peak mefloquine 
concentrations were significantly lower in pregnant than non-pregnant women with falciparum 
malaria compared with treated with a single oral dose of mefloquine (60). Similarly, a dose finding 
study on the Thai-Myanmar border suggests that drug exposure to mefloquine may be decreased in 
late pregnancy (61).   
 
Mean pharmacokinetic parameters of quinine and its metabolites were not significantly different 
between Sudanese pregnant and non-pregnant women with falciparum malaria who received a 
single dose of quinine hydrochloride (as intravenous infusion over 2 hours), suggesting that no dose 
adjustment is required in pregnancy (62). However, in these women exposure to quinine during 
clinical malaria was higher than during the convalescence phase (63). A higher exposure to quinine 
during clinical malaria as compared to the convalescence phase was similarly reported in Ugandan 
pregnant women with falciparum malaria and treated with oral quinine. However, drug exposure 
was about half of those previously reported in non-pregnant patients (36).  
 
The systemic drug exposure to lumefantrine is generally reported to be lower in pregnant than non-
pregnant women treated with artemether-lumefantrine for falciparum malaria (44,64,65). These 
studies demonstrate about 30% decrease in day seven concentrations of lumefantrine in pregnant 
versus non-pregnant patients. However, one study in rural Uganda reported no differences in the 
exposure to lumefantrine between pregnant women and non-pregnant women with falciparum 
malaria (30).  
 
Antifolates 
In Papua New Guinea, the exposures to sulfadoxine and pyrimethamine were significantly lower in 
pregnant than in non-pregnant women (66). A study in Kenya evaluated the pharmacokinetic 
properties of sulfadoxine and pyrimethamine in 33 pregnant women and 11 post-partum women 
and demonstrated similar results for sulfadoxine, while pyrimethamine was unaffected by pregnancy 
(67). A multicentre study (Mali, Mozambique, Sudan, and Zambia) confirmed that sulfadoxine 
exposure was lower during pregnancy than postpartum while reporting higher pyrimethamine 
exposure during pregnancy (68). Pharmacokinetic data of both drugs were highly variable among the 
study sites and did not recommend dose adjustment  (68).  
 
Drug safety (Table 2) 
Firm conclusions on the safety of antimalarial drugs in pregnancy are limited by methodological 
issues. Studies are often underpowered to detect rare safety outcomes and small differences. The 
trial design often covers a short/sporadic follow-up period (69) and lack statistical power to adjust 
for uncontrolled confounders like severity of disease and/or presence of sexually transmitted 
infections, emphasising the need for continuous safety monitoring. 
 
Artemisinin derivatives and partner drugs  
In pregnant rats on gestational day 10, artemisinin derivatives have embryotoxic effects (death, 
cardiac malformations, and long bone malformations) due to the death of circulating embryonic 
erythroblasts (70). In humans, dihydroartemisinin is responsible for the erythro-toxicity (71,72). In 
rats, gestational days 10 to 14 were the most sensitive to the embryolethal effects of artesunate; the 
corresponding gestational age in humans is approximately week three to week nine post-conception 
(73). Artemisinins concentrate in infected red blood cells while malaria causes hypoferremia (74). 
Therefore, malaria may protect against artemisinin-induced decreases in reticulocyte count by 
reducing the target tissue levels of active drug and/or ferrous iron which activates the drug to toxic-
free radicals; malaria protection against artesunate toxicity has been observed in rats. This could be 
true also for embryotoxicity so that pregnant women without malaria would be at greater risk of 
artemisinin-induced embryotoxicity (73).  
A meta-analysis on 1,664 well-documented pregnancies followed after artemisinin or quinine 
treatment during the first trimester reported no differences in the risk of miscarriage, stillbirth, or 
major congenital malformations between artemisinins and quinine (22). Risk of miscarriage was 
similar between women treated with artemisinins during the first trimester and those not treated 
with an antimalarial; the risk was significantly higher for women treated with quinine than in those 
not treated with an antimalarial (22,75). In Thailand, the risk of miscarriage among women attending 
antenatal clinics during the years 1986-2010 was not significantly different in those treated between 
six and 12 weeks of gestation with artesunate (31%), quinine (27%) or chloroquine (26%) (p=0.71) 
(76). The risk of miscarriage associated with malaria outweighed any adverse effects from treatment 
with antimalarials, including artemisinins (76).  
In Thailand, first trimester pregnant women exposed to either artemisinins (n=183) or quinine 
(n=971) had a similar risk of miscarriage. Considering only exposure during the embryo-sensitive 
window (6-13 weeks gestation), the occurrence of congenital malformations for artemisinins or 
quinine was similar although the sample size was small (77). In Kenya (78), Tanzania (79), Zambia 
(80), and Rwanda (81), first trimester exposure was reported in 299, 319, 294, and 96 pregnant 
women, respectively. In Kenya, the risk of miscarriage tended to be higher among women treated 
with artemisinins compared to women with no exposure to antimalarial drugs, though this did not 
apply when considering only exposure during the embryo-sensitive period or when comparing to 
women treated with quinine. In Tanzania, adverse pregnancy outcomes (miscarriage/stillbirth, 
prematurity) were more common in women treated with quinine than with any other antimalarial, 
including artemether-lumefantrine. In Zambia, first trimester exposure to antimalarials was not 
associated with adverse pregnancy outcomes (80). 
 Artemether-lumefantrine in the first trimester of pregnancy did not increase the risk of perinatal or 
neonatal death or stillbirth. Infant neurodevelopment, birth weight, and the overall incidence of 
birth defects were also similar, irrespective of treatment with artemether-lumefantrine or other 
antimalarials during the first trimester. All cases of miscarriage in the artemether-lumefantrine 
exposure group occurred in patients who had received treatment during the first trimester, although 
in most cases there were confounding factors (82). Preclinical data on lumefantrine alone did not 
show any embryotoxicity (36). Nevertheless, artemether-lumefantrine is still not recommended for 
the treatment of malaria during the first trimester of pregnancy unless quinine, with or without 
clindamycin, has failed or is unavailable.     
 
A systematic review and meta-analysis of second and third trimester exposure to ACTs in studies in 
Africa and Asia indicates that the risk of miscarriage and congenital anomalies is similar among 
women in second or third trimester of pregnancy treated with artemisinins and women treated with 
quinine or other non-artemisinin antimalarials. This meta-analysis also reported that the risk of 
stillbirth was lower in ACT compared to quinine recipients, possibly reflecting a higher efficacy of 
artemisinins treatment (83).  
 
In the second and third trimester, artemether-lumefantrine (n=903) was not associated with 
increased adverse pregnancy outcomes as compared with quinine (n=152) or sulfadoxine-
pyrimethamine (n=378), showed improved tolerability relative to quinine, and its efficacy was non-
inferior to quinine (84).  
 
Between 1948 and 1990, only six published studies reported amodiaquine use in pregnancy, and 
only one publication mentioned adverse events but with limited information (85). More recently, 
amodiaquine alone or in combination with sulfadoxine-pyrimethamine during the second or third 
trimester was not associated with liver toxicity or bone marrow depression (86). In Ghana, women 
treated with amodiaquine alone or combined with sulfadoxine-pyrimethamine  reported a higher 
frequency of mild adverse events  but no difference in miscarriages, stillbirths, neonatal jaundice, 
and neonatal deaths (87).  At standard dosages, amodiaquine is not teratogenic and the adverse 
events observed during pregnancy are no greater than those associated with falciparum malaria in 
pregnancy (88). More recent but smaller studies reported amodiaquine to be safe and reasonably 
well tolerated (56). Amodiaquine-artesunate was not associated with adverse birth outcomes (89). 
Similarly, the proportion of women who reported adverse events during the seven days following 
treatment did not differ significantly between treatment groups (IPTp-SP, and treatment with SP or 
amodiaquine-artesunate) with the exception of general weakness, which was reported slightly more 
frequently in women treated with amodiaquine-artesunate (90).   
 
Dihydroartemisinin-piperaquine was well tolerated and had an acceptable safety profile in one arm 
of a recent trial with more than 800 African pregnant women treated in the second and third 
trimester (28). These results confirm other smaller studies carried out in Asia (51,91) and Africa 
(58,59). Although dihydroartemisinin-piperaquine can cause prolongation of the QT interval (92), no 
clinically significant prolongation of the QT interval was seen on 42 pregnant women receiving 
dihydroartemisinin-piperaquine (93,94).  
  
Initial concerns on the association between mefloquine and stillbirth arose as a result of a 
retrospective analysis in Thailand (95).  This finding was not supported by earlier studies evaluating 
mefloquine for treatment of malaria in pregnancy, nor by later studies on mefloquine-artesunate 
(96–98). Birth defect prevalence and foetal loss were comparable with background rates in 2,506 
pregnant women exposed to mefloquine (99). Mefloquine-artesunate was less well tolerated than 
artemether-lumefantrine and dihydroartemisinin-piperaquine, and drug-related adverse events 
were more frequent in 850 African women in the second and third trimester of pregnancy with 
falciparum malaria; pregnancy outcomes were similar to other antimalarial treatments (28).  When 
mefloquine alone was used as intermittent preventive treatment, incidence of spontaneous 
abortions, stillbirths, and congenital anomalies did not differ significantly with the sulfadoxine-
pyrimethamine groups, though adverse events were more frequent (100). Adverse events were 
common, though mostly minor, in 103 HIV-infected and 421 HIV-negative Beninese pregnant women 
to whom mefloquine was administered as intermittent preventive treatment. Interestingly, 
mefloquine tolerability was better in HIV-infected women, a finding possibly explained by these 
women being more familiar with experiencing adverse events and thus less prone to report them 
systematically (101).  In two recent studies for prevention of malaria in African HIV positive and 
negative women, mefloquine was less well-tolerated than sulfadoxine-pyrimethamine (102,103). In 
the HIV positive women study, the viral load and the frequency of mother to child transmission of 
HIV was higher in the mefloquine group but this result needs to be confirmed (104).  
 
Sulfadoxine-pyrimethamine has been used extensively in pregnancy for treatment and intermittent 
preventive treatment, but formal safety studies are limited (36). Pyrimethamine causes dose-
dependent embryotoxicity in rats, but not at human-equivalent doses (105).  In a case-control study, 
mothers whose babies had cleft palate had had a higher exposure to sulfonamide than controls 
(105). Nevertheless, although folate antagonist use in the first trimester is associated with neural 
tube defects, large case-control studies have demonstrated that sulfadoxine-pyrimethamine 
administered as IPTp does not increase the risk of teratogenesis (106). In Malawi (107) and Sudan 
(108), sulfadoxine-pyrimethamine associated with artesunate administered to pregnant women with 
falciparum malaria seemed safe and well tolerated, though the sample size in both countries was 
small. Similarly, in The Gambia, exposure to sulfadoxine-pyrimethamine and a single dose of 
artesunate administered to pregnant women in the context of a mass drug administration exercise 
did not report any teratogenic or other harmful effect  (109). Sulfadoxine-pyrimethamine should not 
be administered concurrently with cotrimoxazole given their redundant mechanisms of action and 
synergistic worsening of adverse drug reactions (110). No clinical association between sulfadoxine-
pyrimethamine and kernicterus has been reported (106).   
 
Quinine 
The use of quinine in pregnancy is generally thought to be safe, and it is not associated with poor 
birth outcomes (36). Quinine has been shown to cause prolongation of the QT interval, but no 
significant cardiotoxicity has been reported in large prospective studies (111). Quinine can 
sometimes cause hypoglycaemia, particularly in the second and third trimester, even in 
uncomplicated malaria (5). In Uganda, the percentage of patients treated for uncomplicated malaria 
during pregnancy with at least one adverse event (most commonly tinnitus) was significantly higher 
in the quinine than in the artemether-lumefantrine arm (25).  
 
Chloroquine 
Chloroquine has been described as safe throughout pregnancy (112). However, chloroquine has 
been shown to cause prolongation of the QT interval but with no significant cardiotoxicity reported 
in large prospective studies (111). A study in Thailand reported that the risk of miscarriage was 
similar for women treated with chloroquine, quinine, or artesunate (76).   
 
Access to treatment 
Despite wide-scale adoption of the 2006 WHO recommendations (113) to use ACTs to treat 
uncomplicated malaria in the second and third trimester of pregnancy, access to parasitological 
diagnosis and/or appropriate antimalarial treatment in many countries and regions remains low. In a 
systematic review of women’s access and provider practices, case management practices among 
healthcare providers in the public, private, and retail sectors were generally poor (114). Reliance on 
clinical diagnosis and poor adherence to treatment policy was consistently reported across different 
cadres and settings (114). Adherence to treatment policy in the first trimester of pregnancy was 
significantly lower (28%) than in other trimesters (72%) (114). ACTs, which are currently 
contraindicated in the first trimester (22,113), were prescribed extensively either alongside quinine 
(recommended policy) (114–117) or exclusively (118). In western Kenya, correct prescription was 
observed in only 24% of first trimester women exiting health facilities and 0% of simulated clients 
attending drug outlets, compared to 65% and 40% in other trimesters, respectively. Notably, 49% of 
first trimester women presenting to drug outlets were prescribed artemether-lumefantrine (116). 
Drugs no longer recommended for treatment of falciparum malaria in Africa were widely prescribed 
for all trimesters, including sulfadoxine-pyrimethamine (restricted for use  as IPTp/prevention only) 
in Nigeria (115,117–119) and Kenya (116), and chloroquine in Nigeria (115,117,119). Use of 
artemether and artesunate monotherapies were widely reported in Nigeria (115,117–119) and in 
Uganda (120).  
Correct treatment practices among health providers were associated with knowledge (119,120), 
training (114,116), availability of guidelines (120), and facility type (public versus private/drug shops) 
(114,116). Prescribing practices were driven by concerns over drug side effects and safety, drug 
availability, patient preference, and cost (114). This research highlights the need for countries to 
provide quality training, guidelines, and job aids to all health professionals and other providers, 
particularly drug shops in the community, and ensure both the diagnostic tools and the 
recommended treatments are available at all levels of the health system. Evidence for quality 
improvement initiatives targeting public and private providers are also needed, alongside legislation 
to regulate which antimalarials are licenced for sale.  
Although pregnant women often report bouts of malaria, anthropological research has highlighted 
how their understandings of malaria symptoms overlap only partially with biomedical definitions 
and can be difficult to distinguish from pregnancy-related symptoms (121–124). Such confusion, for 
example, contributed to delayed treatment seeking in Mali and Kenya (125). Women’s choice of 
healthcare provider was influenced by severity and duration of malaria episode (121,126), 
knowledge and perceptions of drug safety, drug availability, and cost and perceptions of healthcare 
services (114,125), with the use of non-biomedical remedies– homemade or from a local healer – 
reported in Mali (125), Nigeria (127), South Sudan (126), India (128), and Papua New Guinea (129). 
Social relationships influenced treatment seeking and some, particularly younger women, sought 
advice/assistance from relatives (121,124). Observations of self-treatment – prompted by drug or 
diagnostic costs, irregular drug supplies at health facilities, and/or previous poor quality care – 
highlight the need for comprehensible advice on antimalarials and dosages that are safe during 
pregnancy to be made widely available (121). 
Perspectives and conclusions 
Over the last 10 years, the Malaria in Pregnancy Consortium and other research groups have carried 
out extensive research to improve the control of malaria in pregnancy, focussing on previously 
identified priorities (130).  Evidence on the treatment of malaria during pregnancy has increased 
substantially.  Malaria in pregnancy can be adequately diagnosed by HRP2-based RDTs; it has been 
confirmed that available ACTs can be used for the treatment of malaria during the second and third 
trimester of pregnancy; and the WHO may revise the guidelines on the use of artemisinins in the first 
trimester of pregnancy.  It is now essential to translate this evidence into policies. However, poor 
quality service provision across public, private, and retail sectors in most endemic regions indicates a 
pressing need for research to identify quality improvement interventions targeting users and 
providers. The priorities for policy implementation include health provider training on national policy 
guidelines for diagnosis and treatment of malaria in pregnancy. The continued use of monotherapies 
in pregnancy and more generally requires national legislation to prohibit their availability and use. 
Pregnant women need access to information about which antimalarials are safe. 
In addition, there is a need to establish efficient systems for pharmacovigilance able to identify and 
report possible drug-related safety signals. This is particularly problematic in low income countries 
because of specific challenges such as geographical remoteness of many of the health facilities, poor 
telecommunication systems, and inadequate education of health professionals and patients  
(36,131). Safety of medications during pregnancy could be monitored by different prospective 
designs, including pregnancy registers, but these require substantial resources, not readily available 
in malaria-endemic countries. Probabilistic record linkage to assess the risk of major congenital 
malformations and stillbirth could be a possible approach but needs well-kept medical registers 
(132). Adequately addressing these programmatic challenges will require improved dialogue and 
collaboration between researchers, policy makers and funders.  Additional research priorities are 
outlined in Table 3.  
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Table 1. Pharmacokinetic summary 
Antimalarial Study patients Country Pregnancy effects Ref 
Artesunate 
Pregnant women (n 
= 24) 
Thailand Decreased exposure to dihydroartemisinin in 
pregnant women compared to historical 
controls. 
38 
Pregnant and post-
partum women (n = 
20/15) 
Thailand 23% decreased exposure to dihydroartemisinin 
in pregnant women compared to post-partum 
women. 
39, 
40 
Pregnant, post-
partum and non-
pregnant women (n 
= 26/26/25) 
DRC 42% decreased exposure to dihydroartemisinin 
in pregnant women compared non-pregnant 
women.  
41, 
42 
Pregnant and non-
pregnant women (n 
= 24/24) 
Burkina 
Faso 
No difference in exposure to dihydroartemisinin 
in pregnant women compared non-pregnant 
women.  
43 
Contradictory results; generally lower exposure reported in pregnant women. 
 
Artemether 
Pregnant and non-
pregnant women (n 
= 30/30) 
Uganda No difference in exposure to dihydroartemisinin 
in pregnant women compared non-pregnant 
women. 
44 
Pregnant and non-
pregnant women (n 
= 33/22) 
Tanzania No difference in exposure to dihydroartemisinin 
in pregnant women compared non-pregnant 
women. 
45 
Pregnant women (n 
= 21) 
Uganda Decreased exposure to dihydroartemisinin in 
pregnant women compared to historical 
controls. 
45, 
48 
Pregnant women (n 
= 13) 
Thailand Decreased exposure to dihydroartemisinin in 
pregnant women compared to historical 
controls. 
47 
Contradictory results; generally no difference in exposure reported in pregnant women. 
 
Dihydroartemisinin 
Pregnant and non-
pregnant women (n 
= 32/33) 
Papua 
New 
Guinea 
No difference in exposure to dihydroartemisinin 
in pregnant women compared non-pregnant 
women. 
49 
Pregnant and non-
pregnant women (n 
= 24/24) 
Thailand 38% decreased exposure to dihydroartemisinin 
in pregnant women compared non-pregnant 
women. 
50, 
51 
Pregnant and non-
pregnant women (n 
= 31/30) 
Uganda 
 
47% decreased exposure to dihydroartemisinin 
in pregnant women compared non-pregnant 
women. 
52 
Contradictory results; no difference and decreased exposure reported in pregnant women. 
 
Chloroquine 
Pregnant and non-
pregnant women (n 
= 30/30) 
Papua 
New 
Guinea 
34% decreased exposure to chloroquine in 
pregnant women compared non-pregnant 
women. 
54 
Pregnant and non- Thailand No difference in exposure to chloroquine in 55 
Table 1
pregnant women (n 
= 12/15) 
pregnant women compared non-pregnant 
women. 
Pregnant women (n 
= 49) 
Tanzania Decreased exposure to chloroquine in pregnant 
women compared to historical controls. 
133 
Contradictory results; no difference and decreased exposure reported in pregnant women. 
 
Amodiaquine 
Pregnant and post-
partum women (n = 
24/18) 
Thailand No difference in exposure to amodiaquine and 
desethylamodiaquine in pregnant women 
compared to post-partum women. 
56, 
57 
No difference in exposure reported in pregnant women. 
 
Piperaquine 
Pregnant and non-
pregnant women (n 
= 32/33) 
Papua 
New 
Guinea 
42% decreased exposure to piperaquine in 
pregnant women compared non-pregnant 
women. 
49 
Pregnant and non-
pregnant women (n 
= 24/24) 
Thailand No difference in exposure to piperaquine in 
pregnant women compared non-pregnant 
women. 
50, 
51 
Pregnant and non-
pregnant women (n 
= 12/12) 
Sudan No difference in exposure to piperaquine in 
pregnant women compared non-pregnant 
women. 
58, 
59 
Pregnant and non-
pregnant women (n 
= 31/30) 
Uganda 
 
40% decreased exposure to piperaquine in 
pregnant women compared non-pregnant 
women. 
52 
Contradictory results; no difference and decreased exposure reported in pregnant women. 
 
Mefloquine 
Pregnant and non-
pregnant women (n 
= 24/24) 
Burkina 
Faso 
No difference in exposure to mefloquine in 
pregnant women compared non-pregnant 
women.  
43 
Pregnant and non-
pregnant women (n 
= 9/8) 
Burkina 
Faso 
No difference in exposure to mefloquine in 
pregnant women compared non-pregnant 
women.  
60 
Pregnant women (n 
= 20) 
Thailand Decreased exposure to mefloquine in pregnant 
women compared to historical controls. 
61 
Contradictory results; generally no difference in exposure reported in pregnant women. 
 
Quinine 
Pregnant women (n 
= 22) 
Uganda Decreased exposure to quinine in pregnant 
women compared to historical controls. 
45, 
46 
Pregnant and non-
pregnant women (n 
= 8/8) 
Sudan No difference in exposure to quinine in pregnant 
women compared non-pregnant women. 
62 
Pregnant and non-
pregnant women (n 
= 9/8) 
Sudan No difference in exposure to quinine in pregnant 
women compared non-pregnant women. 
63 
Contradictory results; generally no difference in exposure reported in pregnant women. 
 
Lumefantrine 
Pregnant and non-
pregnant women (n 
Uganda No difference in exposure to lumefantrine in 
pregnant women compared non-pregnant 
39 
= 30/30) women. 
Pregnant and non-
pregnant women (n 
= 33/22) 
Tanzania 34% decreased exposure to lumefantrine in 
pregnant women compared non-pregnant 
women. 
44 
Pregnant and non-
pregnant women (n 
= 26/17) 
Uganda No difference in exposure to lumefantrine in 
pregnant women compared non-pregnant 
women. 
45 
Pregnant women (n 
= 13) 
Thailand Decreased exposure to lumefantrine in pregnant 
women compared to historical controls. 
47 
Pregnant and non-
pregnant women (n 
= 116/17) 
Uganda No difference in exposure to lumefantrine in 
pregnant women compared non-pregnant 
women. 
64 
Pregnant women (n 
= 103) 
Thailand Decreased exposure to lumefantrine in pregnant 
women compared to historical controls. 
65 
Contradictory results; generally no difference in exposure reported in pregnant women. 
 
Sulfadoxine 
Pregnant and non-
pregnant women (n 
= 30/30) 
Papua 
New 
Guinea 
33% decreased exposure to sulfadoxine in 
pregnant women compared non-pregnant 
women. 
66 
Pregnant and post-
partum women (n = 
33/11) 
Kenya 43% decreased exposure to sulfadoxine in 
pregnant women compared to post-partum 
women. 
67 
Pregnant and post-
partum women (n = 
43/40) 
Mali, 
Zambia 
No difference in exposure to sulfadoxine in 
pregnant women compared to post-partum 
women. 
68 
Pregnant and non-
pregnant women (n 
= 87/34) 
Uganda 82% decreased exposure to sulfadoxine in 
pregnant women compared non-pregnant 
women. 
134 
Contradictory results; generally decreased exposure reported in pregnant women. 
 
Pyrimethamine 
Pregnant and non-
pregnant women (n 
= 30/30) 
Papua 
New 
Guinea 
32% decreased exposure to pyrimethamine in 
pregnant women compared non-pregnant 
women. 
66 
Pregnant and post-
partum women (n = 
33/11) 
Kenya No difference in exposure to pyrimethamine in 
pregnant women compared to post-partum 
women. 
67 
Pregnant and post-
partum women (n = 
43/40) 
Mali, 
Zambia 
31% increased exposure to pyrimethamine in 
pregnant women compared to post-partum 
women. 
68 
Pregnant and non-
pregnant women (n 
= 87/34) 
Uganda 34% decreased exposure to pyrimethamine in 
pregnant women compared non-pregnant 
women. 
134 
Contradictory results; no difference, increased and decreased exposure reported in pregnant 
women. 
 
Relative difference in exposure calculated as (AUCcomparison – AUCpregnancy) /  AUCcomparison.  
Table 2: Summary of antimalarials safety profile  
 
Drugs Safety profile References 
Artemisinin derivatives 
and partner drugs 
 Artemisinin derivatives in general are well tolerated. 
Concerns regarding safety on pregnancy have limited its 
use in first trimester. Recent studies reported no 
differences in the risk of miscarriage, stillbirth, or major 
congenital malformations between artemisinins and 
quinine used during first trimester. 
 Amodiaquine-artesunate has been associated with 
general weakness, vomiting, dizziness, and nausea but 
without increased risk of miscarriage, stillbirth, or major 
congenital malformations. 
 Dihydroartemisinin-piperaquine is well tolerated. 
Concerns regarding prolongation of the QT interval 
were raised. More studies are needed to understand 
the clinical significance of this event in pregnant 
women.  
 Mefloquine-artesunate was less well tolerated when 
compare with other combinations (artemether-
lumefantrine, dihydroartemisinin-piperaquine).  
 Sulfadoxine-pyrimethamine - artesunate seemed safe 
and well tolerated. 
22, 71, 72, 73, 77, 
83, 85, 89, 91, 93, 
94, 107, 109. 
 
 
Mefloquine  Mefloquine is reported to be less well-tolerated 
(increased risk of dizziness and vomiting) than 
sulfadoxine-pyrimethamine when used for prevention 
of malaria.  
 When mefloquine alone was used as intermittent 
preventive treatment, incidence of spontaneous 
95, 96, 97, 98, 99, 
101, 103, 104, 
108, 112. 
 
 
Table 2
abortions, stillbirths, and congenital anomalies did not 
differ significantly compared to sulfadoxine-
pyrimethamine. 
Sulfadoxine-
pyrimethamine 
 Sulfadoxine-pyrimethamine should not be 
administered concurrently with cotrimoxazole given 
their redundant mechanisms of action and synergistic 
worsening of adverse drug reactions particularly 
cutaneous reactions.   
 Was reported to be associated with neural tube defects 
when used in first trimester, but when administered as 
IPTp in the second and third trimesters does not result 
in an increased risk of teratogenesis.  
86, 87, 106, 110. 
 
 
Quinine 
 
 Quinine is less well tolerated when comparing with 
other antimalarials and can cause hypoglycaemia and 
tinnitus, particularly in the second and third trimester. 
Prolongation of the QT interval with no significant 
cardiotoxicity has been reported.  
105, 111. 
 
 
Chloroquine 
 
 Chloroquine has been described as safe throughout 
pregnancy.  
 The risk of miscarriage was similar for women treated 
with chloroquine, quinine, or artesunate.   
105, 112. 
 
 
 
 
 
 
 
Table 3. Recommendations for policy and future research 
Topic/programme area Policy implementation Future research 
Diagnosis  Assess extent to which 
diagnosis of malaria in 
pregnancy is practiced across 
public and private providers 
 Stratify pregnant women in 
numerator/denominator for 
parasite confirmed malaria in 
HMIS 
 Ensure availability to sensitive 
diagnostic tests e.g. HRP2-
based RDTs 
 Evaluate ultra-sensitive RDT 
(Alere™ Malaria Ag P.f) for 
detection of infections in 
pregnancy 
 Develop other more 
sensitive diagnostic tests for 
all Plasmodium species 
Treatment of 
uncomplicated malaria 
in pregnancy 
 Systematic assessment of the 
quality of case management of 
MiP practices across public and 
private service providers 
 Review pre-service and in-
service training curriculae 
 Provide quality training, 
guidelines, and job aids for 
health providers 
 Education of pregnant women 
on drug safety and side effects 
in pregnancy 
 Treatment of uncomplicated 
non-falciparum malaria, 
including treatment of liver 
stages 
Treatment of severe 
malaria in pregnancy 
  Treatment of severe non-
falciparum malaria in 
pregnancy 
Pharmacovigilance   National post marketing 
surveillance of ACTs in all 
trimesters of pregnancy 
 Global pregnancy registry for 
drug safety including 
antimalarials (WHO) 
 
 Develop cost-efficient 
pharmacovigilance systems 
suitable for low income 
countries e.g.  probabilistic 
record linkage 
 Continued 
pharmacovigilance for first 
trimester exposure to 
antimalarials to better 
estimate the risk of major 
congenital malformations 
Pharmacokinetics   Optimization of ACT dosages 
in pregnancy 
Drug resistance  Drug resistance surveillance 
monitoring 
 Legislation to prevent 
availability and use of 
monotherapies 
 
 New treatment alternatives 
to ACTs given the recent 
emergence of multidrug 
resistance 
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